NCT07259733Recruiting
Rapid Management of Resistant Hypertension in the Public Health System (Fast Control)
Strategy for Rapid Control of Apparent Resistant Arterial Hypertension in the Public Health System (FAST Control)
Source: ClinicalTrials.gov · Last updated 2 Dec 2025
Brief summary (registry, in English)
This is a single-center, open-label, randomized clinical trial conducted at the Instituto Dante Pazzanese de Cardiologia, São Paulo, Brazil. The study evaluates a simplified treatment strategy for patients with apparent resistant hypertension, comparing fixed triple combination therapy (perindopril, indapamide, and amlodipine) with usual care using multiple separate antihypertensive drugs. The primary objective is to compare 24-hour blood pressure control as measured by ABPM at 12 weeks between the two treatment strategies. Enrollment began on July 15, 2023, and this study was registered retrospectively.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 142 (estimated)
- First submitted
- 21 Nov 2025
- Start date
- 15 Jul 2023
- Primary completion date
- 31 Dec 2026
- Lead sponsor
- Instituto Dante Pazzanese de Cardiologia
- Diseases
- High blood pressure
- NCT number
- NCT07259733
What you commit to
- Study type: Interventional
- Planned participants: 142
- From 15 Jul 2023 to the primary completion date, 31 Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Significant valvular heart disease;
- Severe psychiatric disorders;
Lab values
- History of intolerance or adverse reactions to study medications, such as ACE inhibitors (cough or angioedema), thiazide or thiazide-like diuretics (electrolyte disturbances), or calcium channel blockers (significant ankle edema or headache);
- Reduced left ventricular ejection fraction (LVEF \< 55%);
- Severe renal impairment (creatinine clearance \< 30 mL/min or eGFR \< 30 mL/min/1.73 m²);
Age
- Active malignancy with life expectancy \< 2 years;
Other
- Indispensable use of beta-blockers or mineralocorticoid receptor antagonists;
- Office blood pressure ≥ 220 × 120 mmHg;
- Atrial fibrillation or atrial flutter;
- Use of oral anticoagulants;
- Body mass index (BMI) ≥ 40 kg/m²;
- Pregnant or breastfeeding women;
- \-
Who the study is looking for
- Treatment with 3 to 5 classes of antihypertensive drugs, including a maximum dose of an ACE inhibitor or ARB, a thiazide or thiazide-like diuretic, and a calcium channel blocker (CCB);
- Recent 24-hour ambulatory blood pressure monitoring (ABPM) (\<1 month) showing values above target (24-hour BP ≥130/80 mmHg);
- Office blood pressure ≥140/90 mmHg;
- Poor adherence to treatment, defined as a score ≥1 point on the Morisky Medication Adherence Scale (MMAS-4).
- \-
Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Instituto Dante Pazzanese de Cardiologia Coordinator of this site? Confirm its status | São Paulo | Brazil | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.